Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$311.41 USD

311.41
1,625,478

+2.96 (0.96%)

Updated May 14, 2024 04:00 PM ET

After-Market: $311.50 +0.09 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Can Amgen (AMGN) Be a Top Choice for Value Investors?

by Zacks Equity Research

Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

    Coherus Offers Positive Phase III Data on Humira Biosimilar

    by Zacks Equity Research

    Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.

      Arpita Dutt headshot

      Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short

      by Arpita Dutt

      Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.

        Amgen: Phase III Data on Hyperparathyroidism Drug Published

        by Zacks Equity Research

        Amgen Inc. (AMGN) announced that data from three phase III studies on its pipeline candidate, Parsabiv (etelcalcetide), were published in the Journal of the American Medical Association (JAMA).

          Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer

          by Zacks Equity Research

          Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy, Keytruda, has been accepted under priority review by the FDA.

            Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China

            by Zacks Equity Research

            Kite Pharma (KITE) announced that it has entered into a strategic partnership with Daiichi Sankyo to develop and commercialize axicabtagene ciloleucel (KTE-C19) in Japan.

              Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit

              by Zacks Equity Research

              Amgen Inc. (AMGN) announced a new six-year sourcing and supply agreement with DaVita Inc. (DVA) to supply Epogen and Aranesp to meet the latter???s requirements.

                Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)

                by Zacks Equity Research

                Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.'s (ABBV) Humira.

                  Pfizer's Humira Biosimilar Meets Primary Endpoint in Study

                  by Zacks Equity Research

                  Pfizer, Inc. (PFE) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar of Humira approved for the treatment of patients with rheumatoid arthritis.

                    Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

                    by Zacks Equity Research

                    The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

                      The Zacks Analyst Blog Highlights: Comcast, Amgen, General Mills, Target and Ford

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Comcast, Amgen, General Mills, Target and Ford

                        Arpita Dutt headshot

                        Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation

                        by Arpita Dutt

                        Although this was a relatively slow week for the biotech sector, Inotek (ITEK) made it to the headlines on disappointing data on its lead pipeline drug.

                          Kite Pharma (KITE) to Move Cancer Candidate into Phase I

                          by Zacks Equity Research

                          Kite Pharma, Inc. (KITE) announced that it has filed a Investigational New Drug (IND) application with the FDA to initiate phase I studies on KITE-718, a TCR candidate targeting MAGE in a solid tumor.

                            Sheraz Mian headshot

                            Stock Research Reports for Comcast, Amgen & General Mills

                            by Sheraz Mian

                            Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Amgen (AMGN) and General Mills (GIS).

                              Merck (MRK) Does Well in 2016: Reasons for Outperformance

                              by Zacks Equity Research

                              Merck & Co. Inc.'s (MRK) share price is up 12.1%, so far this year.

                                Ligand (LGND) Signs Licensing Deals with Ono and Novartis

                                by Zacks Equity Research

                                Ligand Pharmaceuticals announced that it has entered into a worldwide license agreement with Ono Pharmaceutical under which Ono will use its OmniAb platform for the discovery of fully human mono- and bispecific antibodies.

                                  Bristol-Myers, PsiOxus Ink Deal for Oncolytic Virus Therapy

                                  by Zacks Equity Research

                                  Bristol-Myers (BMY) inks a deal with PsiOxus for an early-stage oncolytic virus candidate, NG-348.

                                    Amgen Files for Approval of Osteoporosis Drug in Japan

                                    by Zacks Equity Research

                                    Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that they have submitted an application seeking marketing approval for its investigational monoclonal antibody romosozumab to Japan's Pharmaceuticals and Medical Devices Agency (PMDA).

                                      Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer

                                      by Zacks Equity Research

                                      Merck & Co., Inc. (MRK) announced that its anti-PD-1 therapy, Keytruda, was rendered a positive opinion in the EU for the first-line treatment of metastatic lung cancer.

                                        Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study

                                        by Zacks Equity Research

                                        Pfizer, Inc. (PFE) announced that it received FDA approval for crisaborole topical ointment to treat mild-to-moderate eczema, or atopic dermatitis, in patients two years and older. The ointment will be sold under the brand name Eucrisa.

                                          Stock Market News for December 08, 2016

                                          by Zacks Equity Research

                                          The Trump induced rally continued to boost major benchmarks to finish at all-time record highs on Wednesday offsetting the decline in healthcare stocks.

                                            Arpita Dutt headshot

                                            Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus

                                            by Arpita Dutt

                                            This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.

                                              AbbVie (ABBV) Presents Impressive Imbruvica Data at ASH

                                              by Zacks Equity Research

                                              AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, presented encouraging results on their cancer drug Imbruvica at the annual meeting of the American Society of Hematology.

                                                Amgen/Allergan File for EU Approval of Avastin Biosimilar

                                                by Zacks Equity Research

                                                Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

                                                  Merck's Keytruda Gets Priority Review for Hodgkin Lymphoma

                                                  by Zacks Equity Research

                                                  Merck & Co., Inc.'s (MRK) supplemental Biologics License Application (sBLA) ??? the second this week ??? for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.